跳至主要内容
临床试验/ITMCTR2200005760
ITMCTR2200005760尚未招募未知

A double-blind, randomized, dose-finding trial of He's Yangchao Granules in the treatment of infertile female with decreased ovarian reserve

适应症

试验速览

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
25 至 45(—)
性别
Female

入选标准

  • 1.Female infertility patients (including patients with primary or secondary infertility) who are aged 25 to 45 years and will attend the gynecology clinic of our hospital; 2.Diagnosis in line with DOR (refer to Obstetrics and Gynecology (9th edition), Reproductive Endocrinology (2nd edition), and combined with clinical, is formulated as follows): (1)Basic Follicle Stimulating Hormone (FSH): 10 -40IU/L, or Follicle Stimulating Hormone (FSH)/Luteinizing Hormone (LH)>3); (2) The number of antral follicles (AFC) determined by vaginal ultrasound is less than 5; (3) AMH 0.5-1.1ng/ml (4) Clinical symptoms: Menstrual cycle exists, but menstrual period, menstrual volume, color quality change; waist and knee soreness, hot flashes and night sweats, insomnia and dreaminess, dizziness, tinnitus, irritability, palpitations, fatigue and other symptoms. If it meets (1),(2),(3),(4),it can be diagnosed. 3.Approved by the hospital ethics committee, all patients gave informed consent.

排除标准

  • 1.Patients have participated in other clinical trials within 3 months; 2.Exclude uncontrollable and/diagnosed medical conditions that may interfere with or affect the research and treatment, such as severe liver, kidney, heart and brain diseases; uncontrolled hypertension, diabetes; 3.Taking drugs that affect hormone metabolism in the past 3 months, such as contraceptives, glucocorticoids, estrogen, thyroid hormone, calcitonin, bisphosphonates, vitamin D, calcium-containing drugs, barbiturates, traditional Chinese medicine, Chinese patent medicine, etc.; 4.Patients with chromosomal abnormalities in peripheral blood; 5.Patients with mental illness who cannot cooperate; 6.No bad habits such as smoking and alcohol abuse.

研究者

相似试验

招募中
1 期
A double-blind, randomised, dose-finding trial to assess the efficacy, safety and pharmacokinetics of a single dose of albaconazole versus fluconazole and placebo in the treatment of acute Candida vulvovaginitisAcute vulvovaginal candidiasisMedDRA version: 20.1Level: PTClassification code: 10047784Term: Vulvovaginal candidiasis Class: 100000004862
CTIS2023-504727-32-00Palau Pharma S.L.500
进行中(未招募)
1 期
A study to evaluate the change in weight after 24 weeks treatment with LIK066 in obese or overweight adults
EUCTR2016-002868-14-ATovartis Pharma AG600
进行中(未招募)
1 期
A study to evaluate the change in weight after 24 weeks treatment with LIK066 in obese or overweight adultschange in weight in obese or overweight adultsMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2016-002868-14-HUovartis Pharma AG600
进行中(未招募)
1 期
A study to evaluate the change in weight after 24 weeks treatment with LIK066 in obese or overweight adultschange in weight in obese or overweight adultsMedDRA version: 20.0Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0Level: PTClassification code 10033307Term: OverweightSystem Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2016-002868-14-SKovartis Pharma AG600
进行中(未招募)
1 期
A study to evaluate the change in weight after 24 weeks treatment with LIK066 in obese or overweight adultschange in weight in obese or overweight adultsMedDRA version: 20.0 Level: PT Classification code 10029883 Term: Obesity System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0 Level: PT Classification code 10033307 Term: Overweight System Organ Class: 10027433 - Metabolism and nutrition disorders
EUCTR2016-002868-14-GBovartis Pharma AG460